The Science of Staying Healthy® - SIGNUM...
Transcript of The Science of Staying Healthy® - SIGNUM...
Signum Dermalogix, Inc. www.signumdermalogix.com
The Science of Staying Healthy®
The Science of Staying Healthy®
Signum Dermalogix, Inc. www.signumdermalogix.com
1
ignum Dermalogix is a spin‐out of Signum Biosciences, a private biotech company founded in
2004 based on technologies developed by Dr. Jeffry Stock at Princeton University. In 8+ years, we have developed in vitro assay systems and robust analytical expertise including safety, efficacy and
claim substantiation for cosmetics, nutraceuticals and pharmaceuticals. We specialize in producing customized cosmetic claim support and/or efficacy dermatological tests providing
robust scientific data to support advertising or packaging claims. In addition, we can provide
thorough safety testing for your molecule and determine its dermal penetration profile, stability and pre‐formulation compatibility via our analytical support team (HPLC, LC‐MS and NMR).
Our expertise is also based on standard validated assays in order to assess your molecule/ingredient
in well‐recognized tests.
Signum Dermalogix is now bringing these assays and services to you the consumer through this
catalog which describes in more detail:
Standard assay systems
Compound profile screening
Analytical services
Customized screening that can be developed upon the client’s request
Signum Dermalogix is the solution to streamline and optimize your R&D screening, management,
and/or customized research at a reduced cost. We provide superior service to differentiate your compound/ingredient. We will provide the scientific excellence and quality your product deserves.
Contact us today.
Signum Dermalogix, Inc. www.signumdermalogix.com
2
3
4
5
6
6
7
7
7
7
STANDARD ASSAY SYSTEMS
Skin Inflammation
Skin Aging
Pollutant Toxicity
Anti‐Microbial
Anti‐Oxidant
Skin Whitening
Skin Tanning
Wound Healing
Metabolism
Safety Testing 8
SIGNUM CUSTOMIZED SCREENING SERVICES 9
SIGNUM COMPOUND PROFILE SCREENING SERVICES 10
SIGNUM ANALYTICAL SERVICES SERVICES 11
Signum Dermalogix, Inc. www.signumdermalogix.com
3
SKIN INFLAMMATION Catalog # Cell line Stimulus/Inducer Endpoint Method eference
SKI‐001 Human Reconstructed Epidermis (EpiDerm) TPA/PMA IL‐8
ELISA, WB, IHC Clobetasol
SKI‐002 Human Reconstructed Epidermis (EpiDerm) TPA/PMA PGE‐2
ELISA, WB, IHC Indomethacin
SKI‐003 Human Reconstructed Epidermis (EpiDerm) UVB IL‐8
ELISA, WB, IHC Clobetasol
SKI‐004 Human Reconstructed Epidermis (EpiDerm) UVB
Sunburn Cells IHC Vitamin C
SKI‐005 Human Reconstructed Epidermis (EpiDerm) UVB
DNA pyrimidine dimers IHC Vitamin C
SKI‐006 Human Reconstructed Epidermis (EpiDerm) UVB/UVA
Lipid Peroxide IHC Vitamin C
SKI‐007 Human Epidermal
Keratinocytes (NHEK) TPA/PMA IL‐8 ELISA, WB,
IF Clobetasol
SKI‐008 Human Epidermal
Keratinocytes (NHEK) TPA/PMA PGE‐2 ELISA, WB,
IF Indomethacin
SKI‐009 Human Epidermal
Keratinocytes (NHEK) UVB IL‐8 ELISA, WB,
IF Clobetasol
SKI‐010 Human Epidermal
Keratinocytes (NHEK) UVB Sunburn Cells IHC Vitamin C
SKI‐011 Human Epidermal
Keratinocytes (NHEK) UVB
DNA pyrimidine dimers IHC Vitamin C
SKI‐012 Human Epidermal
Keratinocytes (NHEK) H2O2 phospho‐
JNK IHC SP600125
SKI‐013 Human Epidermal
Keratinocytes (NHEK) UVB phospho‐
JNK IHC Vitamin D3
SKI‐014 Human Epidermal
Keratinocytes (NHEK) IL‐1alpha IL‐8 ELISA, WB,
IF Clobetasol
SKI‐015 Human Epidermal
Keratinocytes (NHEK) ATP‐gS IL‐6 ELISA, WB,
IF Clobetasol
SKI‐016 Peripheral Blood
Mononuclear Cells (PBMC) CD3/CD28 IL‐4 ELISA TGF‐beta
SKI‐017 Peripheral Blood
Mononuclear Cells (PBMC) CD3/CD28 IL‐17 ELISA TGF‐beta
SKI‐018
Human Dermal Microvascular Endothelial
Cells (HDMEC) ATP‐gS MCP‐1 ELISA Clobetasol
Signum Dermalogix, Inc. www.signumdermalogix.com
4
SKI‐019 Human Dermal Microvascular Endothelial
Cells (HDMEC) anti‐microbial peptides(LL‐37)
IL‐6 ELISA Clobetasol
SKI‐020 Human Epidermal
Keratinocytes (NHEK) P. acnes IL‐8 ELISA Dexamethasone
SKIN AGING Catalog # Cell line Stimulus/Inducer Endpoint Method Reference
SKA‐001 Human Epidermal
Keratinocytes (NHEK) Cell Confluence Keratin‐1 WB Adapalene
SKA‐002 Human Epidermal
Keratinocytes (NHEK) Cell Confluence Keratin‐1 WB Adapalene
SKA‐003 Human Epidermal
Keratinocytes (NHEK) Cell Confluence Filaggrin WB Adapalene
SKA‐004 Human Epidermal
Keratinocytes (NHEK) Cell Confluence Loricrin WB Adapalene
SKA‐005 Human Adult Dermal Fibroblasts (HDF‐a) Basal Collagen ELISA, WB Vitamin C
SKA‐006 Human Adult Dermal Fibroblasts (HDF‐a) Basal Elastin ELISA, WB Vitamin C
SKA‐007 Human Adult Dermal Fibroblasts (HDF‐a) UVA Collagen ELISA, WB Vitamin C
SKA‐008 Human Adult Dermal Fibroblasts (HDF‐a) UVA Elastin ELISA, WB Vitamin C
SKA‐009 Human Adult Dermal Fibroblasts (HDF‐a) H2O2 Collagen ELISA, WB Vitamin C
SKA‐010 Human Adult Dermal Fibroblasts (HDF‐a) H2O2 Elastin ELISA, WB Vitamin C
SKA‐011 Human Adult Dermal Fibroblasts (HDF‐a) Basal Fibronectin ELISA, WB TGF‐beta
SKA‐012 Human Adult Dermal Fibroblasts (HDF‐a) Basal Laminin ELISA, WB TGF‐beta
SKA‐013 Human Adult Dermal Fibroblasts (HDF‐a) UVA Fibronectin ELISA, WB TGF‐beta
SKA‐014 Human Adult Dermal Fibroblasts (HDF‐a) UVA Laminin ELISA, WB TGF‐beta
SKA‐015 Human Adult Dermal Fibroblasts (HDF‐a) H2O2 Fibronectin ELISA, WB TGF‐beta
SKA‐016 Human Adult Dermal Fibroblasts (HDF‐a) H2O2 Laminin ELISA, WB TGF‐beta
SKA‐017 Human Adult Dermal Fibroblasts (HDF‐a) Basal
Hyaluronic acid ELISA, WB TGF‐beta
SKA‐018 Human Adult Dermal Fibroblasts (HDF‐a) Basal
Hyaluronic acid ELISA, WB TGF‐beta
SKA‐019 Human Adult Dermal Fibroblasts (HDF‐a) UVA
Hyaluronic acid ELISA, WB TGF‐beta
Signum Dermalogix, Inc. www.signumdermalogix.com
5
SKA‐020 Human Adult Dermal Fibroblasts (HDF‐a) H2O2
Hyaluronic acid ELISA, WB TGF‐beta
SKA‐021 Human Adult Dermal Fibroblasts (HDF‐a) Basal MMP‐1 ELISA Dexamethasone
SKA‐022 Human Adult Dermal Fibroblasts (HDF‐a) UVA MMP‐1 ELISA Dexamethasone
SKA‐023 Human Adult Dermal Fibroblasts (HDF‐a) H2O2 MMP‐1 ELISA Dexamethasone
SKA‐024 Human Adult Dermal Fibroblasts (HDF‐a) in vitro wound
Cell Migration IF FCS
SKA‐025 Human Reconstructed Epidermis (EpiDerm) Basal
Keratin‐1,10 IHC Adapalene
POLLUTANT TOXICITY Catalog # Cell line Stimulus/Inducer Endpoint Method Reference
TOX‐001 Human Reconstructed Epidermis (EpiDerm) Cadmium/Nickel
MTT Reduction Colorimetric EGF
TOX‐002 Human Epidermal Keratinocytes
(NHEK) Cadmium/Nickel MTT
Reduction Colorimetric EGF
TOX‐003 Human Adult Dermal Fibroblasts (HDF‐a) Cadmium/Nickel
MTT Reduction Colorimetric TGF‐beta
TOX‐004 Human Dermal Microvascular Endothelial Cells (HDMEC) Cadmium/Nickel
MTT Reduction Colorimetric Glucose
TOX‐005 Human Dermal Microvascular Endothelial Cells (HDMEC) Nickel IL‐6 ELISA Clobetasol
TOX‐006 Human Dermal Microvascular Endothelial Cells (HDMEC) Nickel IL‐8 ELISA Clobetasol
Signum Dermalogix, Inc. www.signumdermalogix.com
6
ANTI‐MICROBIAL Catalog # Cell line Stimulus/Inducer Endpoint Method Reference
AMIC‐001 Human Epidermal
Keratinocytes (NHEK) Basal LL‐37 IHC
AMIC‐002 Human Epidermal
Keratinocytes (NHEK) LPS IL‐8 ELISA, WB,
IF Doxycycline
AMIC‐003 Human Umbilical Vein
Endothelial Cells (HUVEC) LPS IL‐8 ELISA, WB,
IF Doxycycline
AMIC‐004 P. acnes Basal Cell death OD Doxycycline
AMIC‐005 S. epidermidis Basal Cell death OD Doxycycline
AMIC‐006 E. coli Basal Cell death OD Doxycycline
ANTI‐OXIDANT Catalog # Cell line Stimulus/Inducer Endpoint Method Reference
AOX‐001 Human Neutrophils HL‐60 fMLP/PMA
Cell Oxidative Burst Colorimetric Vitamin E
AOX‐002 N/A Basal TBARS Colorimetric Trolox
AOX‐003 N/A Basal LDL
Oxidation Colorimetric Vitamin C
AOX‐004 N/A Basal Microsome Oxidation Colorimetric Vitamin C
Signum Dermalogix, Inc. www.signumdermalogix.com
7
SKIN WHITENING
Catalog # Cell line Stimulus/Inducer Endpoint Method Reference
SKW‐001 Human Reconstructed
Epidermis (MelanoDerm) Basal Melanin Colorimetric Kojic Acid/ Iklen Rucinol
SKW‐002 Epidermal Melanocytes Basal Melanin Colorimetric Kojic Acid/ Iklen Rucinol
SKIN TANNING
Catalog # Cell line Stimulus/Inducer Endpoint Method Reference
SKT‐001 Human Reconstructed
Epidermis (MelanoDerm) Basal Melanin Colorimetric IBMX
SKT‐002 Epidermal Melanocytes Basal Melanin Colorimetric IBMX
WOUND HEALING
Catalog # Cell line Stimulus/Inducer Endpoint Method Reference
WH‐001 Human Epidermal
Keratinocytes (NHEK) Cell Confluence Keratin‐1 WB Adapalene
WH‐002 Human Epidermal
Keratinocytes (NHEK) in vitro wound Cell
Migration IF EGF
Signum Dermalogix, Inc. www.signumdermalogix.com
8
METABOLISM
Catalog # Cell line Stimulus/Inducer Endpoint Method Reference
MET‐001 Human Epidermal
Keratinocytes (NHEK) Basal Mitochondrial localization IF FCS
MET‐002 Human Reconstructed Epidermis (EpiDerm) Basal
Mitochondrial localization IF FCS
MET‐003 Human Epidermal
Keratinocytes (NHEK) Basal Ki66, Epsin 3 IF EGF
MET‐004 Human Reconstructed Epidermis (EpiDerm) Basal Ki66, Epsin 3 IF EGF
SAFETY TESTING
Catalog # Cell line Stimulus/Inducer Endpoint Method Reference
SAF‐001 Human Reconstructed Epidermis (EpiDerm) Basal Skin Irritation
Colori‐ metric SDS
SAF‐002 Human Reconstructed Skin
(EpiDerm FT) UVA Photodamage IHC Chlorpro‐ mazine
SAF‐003 Human Reconstructed Skin
(EpiDerm FT) UVB Photodamage IHC Sun
Screen
SAF‐004 Human Reconstructed Skin
(EpiDerm FT) IR‐A Photodamage IHC Vitamin C
SAF‐005 Human Reconstructed Epidermis (EpiOcular) Basal
Animal‐free “Draize” Test
Colori‐ metric SDS
SAF‐006 Mouse BALB/3T3 Fibroblasts UVA Cell Viability Neutral
Red Assay Chlorpro‐ mazine
SAF‐007 Human Epidermal
Keratinocytes (NHEK) Basal Cell Viability MTS Assay SLS
SAF‐008 N/A Daylight: D65 Chemical
Degradation HPLC
quinine mono‐hydrochloride dihydrate
Signum Dermalogix, Inc. www.signumdermalogix.com
9
Standard dermatological tests while effective in many respects do not always provide the best path
forward in characterizing the activity of your molecule or product. Given our past experience in
working to develop and commercialize cosmetics, extracts, pharmaceuticals and nutraceuticals, we
possess innovative capabilities in protocol design, assay development and claim support testing.
With the support of our knowledgeable project management team, we can demonstrate the
activity of your molecule or product and tailor the appropriate assay systems to produce exciting
scientific data to deliver your study objectives and support your product’s brand goals. Contact us
today to select the tests that best fit the vision and criteria of your compound. Together, we will
develop the appropriate dermatology assay project that will provide you with robust scientific
reasoning, results and claims for your product.
Design Characterization
AnalysisOptimization
Signum Dermalogix, Inc. www.signumdermalogix.com
10
Catalog # Cell line Stimulus/Inducer Endpoint Method Reference
Profile‐001 Multiple Several Multiple Several Assay specific
To identify and/or characterize molecules that have beneficial effects on skin cells, Signum
Dermalogix has developed a broad based screen to test your compound, ingredient or extract. This
initial screening strategy is employed to assess a small molecule’s activity and comparing it to
several standard reference compounds that are broad acting in their activities, since the dermal
inflammatory response is realized through interplay between a numbers of different cell types:
keratinocytes, endothelial cells, fibroblasts and various leukocytes. Initial profiling efforts test the
effects of compounds in several commonly accepted cellular models of inflammation utilizing a
number of these cell types. In addition to measuring inhibitory effects of various markers of
inflammation, testing for antimicrobial activity and evaluating effects on keratinocyte
differentiation is also performed. Altogether this initial characterization will determine your
compound of interest’s activities over a broad number of cellular systems and molecular endpoints.
This type of profiling is especially valuable in identifying potentially new or additional claims for
your molecule that may have previously been missed or during early stage discovery.
This screening program will*:
Identify the skin and immune cell types affected by the compound
Discover the specific molecular processes that are modulated by the compound
Determine if the small molecule has anti‐bacterial activity versus skin flora
Determine activity of each molecule in regulating cellular processes & microbial growth
Discover the viability of several skin & immune cell types in the presence of the compound
Determine if the compound has anti‐oxidant properties
*Signum Dermalogix can customize screening to your own specification and target(s) of interest. Assays may be
swapped if specific tests listed in our standard assay system are of greater interest for studying your molecule.
Signum Dermalogix, Inc. www.signumdermalogix.com
11
Once a compound or product is found to be effective in vitro, the next steps in development for skin
care call for the compound to be formulated to assess it dermal penetration profile, stability and
further safety testing. In addition to custom assay development and characterizing the activity and
safety profile of your compound or product, Signum Dermalogix provides analytical and testing
services including:
Analytical support (HPLC, LC‐MS, NMR)
Method development
Stability assessment
Radioisotope labeling
Franz cell dermal penetration studies
Pre‐formulation assessment
In vivo safety assessment
We maintain an NRC license to use radioisotopes and have an Institutional Animal Care and Use
Committee (IACUC) in place for SOP approval and compliance with animal safety testing
regulations. Early development and precise strategy can reduce costs and accelerate timelines.
Contact us to learn more about our services and where Signum Dermalogix can bring maximum
benefit to your development program and product.
Catalog # Cell line Stimulus/Inducer Endpoint Method Reference
SPEN‐001 Pig Skin (ex vivo) Basal Skin layer levels Franz Cell Vehicle
Signum Dermalogix, Inc. www.signumdermalogix.com
12
Eduardo Perez, PhD
Chief Scientific Officer
732‐329‐6344 ext. 203
The Science of Staying Healthy®